Cancer immunotherapy has taken center stage in the fight against cancer. The mAb and their related counterparts remain at the forefront of cancer immunotherapy applications. However, new and improved therapeutics and/or treatment methods that may overcome their production, administration, and pharmacological limitations, including the evolution of treatment resistance are still in widespread demand. Key to the development of technological innovations that may overcome these limitations are small to intermediate size molecules with the targeting and effector functions of antibodies. Towards this goal, our research objective is to mimic antibody targeting and effector functions with semi-synthetic peptide-protein bioconjugates. In this application, the peptide sequence, Pep42, has been selected to target the Glucose Regulated Protein of 78 kilodalton (GRP78) on the surface of tumors but not on healthy tissues. The selected tumor antigen, B7-H6, exhibits NKp30 receptor binding on NK cells and immunostimulatory activity by the release of inflammatory cytokines that ultimately trigger tumor lysis and death. However, the downregulation or shedding of B7-H6 from tumors reduces NKp30 activation of NK cells, ultimately diminishing their anti-tumor immune responses. Therefore, we propose the development of new Pep42-B7-H6 conjugates that provide effective NK cell targeting and killing of GRP78 overexpressing tumors that lack cell surface B7-H6. The proposed project will be addressed by two specific aims: 1) the preparation of the Pep42-B7-H6 conjugates and 2) evaluation of their anti-cancer effects. Significantly, the Pep42-B7-H6 conjugates are anticipated to potentiate cancer immunotherapy of resilient tumors that evade NK cell-dependent immunity while providing insights into the production of semi-synthetic antibody mimics.

Public Health Relevance

The annual report on Cancer Facts and Figures by the American Cancer Society, anticipates 1, 685, 210 new cancer cases and 595, 690 cancer deaths in 2016 making cancer the second most common cause of death in the United States. Among the greatest challenges in cancer therapy is the ability to overcome treatment resistance which often leads to aggressive tumor recurrence, metastasis and mortality. In this small research grant application, an innovative approach featuring the acitvation of NK cells is anticipated to provide a break-through in cancer research by potentiating tumor treatment efficacy while overcoming NK-dependent immunotherapy resistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
5R03CA216136-02
Application #
9514023
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Sommers, Connie L
Project Start
2017-06-22
Project End
2019-05-31
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Seton Hall University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
079324315
City
South Orange
State
NJ
Country
United States
Zip Code
07079